TUSTIN, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for hepatitis C infection and cancer, today announced that it will release its first quarter FY 2007 financial results on September 11, 2006 at 7:00am EDT, and will host a conference call and webcast to discuss the results at 11:00 a.m. on the same day. Participating members of Peregrine senior management will include president and chief executive officer Steven W. King and chief financial officer Paul Lytle. Management will discuss financial results for the quarter and review recent operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the live or archived webcast.

The conference call and live webcast will begin at 11:00 a.m. EDT/8:00 a.m. PDT.

To listen to a live broadcast of the call over the Internet or to review the archived call, please visit: www.peregrineinc.com. The webcast will be archived on Peregrine's website for 30 days.

To listen to the call via telephone, please call the following number approximately 10 minutes prior to the scheduled time of the conference call: 1-800-860-2442. A telephonic replay of the conference call will be available through September 18, 2006 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical trials in cancer and HCV infection with its lead product candidate bavituximab and Cotara®. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

SOURCE Peregrine Pharmaceuticals, Inc.

CONTACT: investors, Barbara Lindheim, +1-800-987-8256, info@peregrineinc.com, or media, Stephen Gendel, +1-212-918-4650, both of GendeLLindheim BioCom Partners, for Peregrine Pharmaceuticals, Inc.
Web site: http://www.peregrineinc.com